ALUR News - Candlesense

Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and ...

How will the announced business update affect analyst sentiment and potential changes in target price recommendations? What are the key risks associated with the new strategic direction, including clinical trial outcomes and partnership execution? How might the strategic shift toward muscle‑mass maintenance influence the company’s product portfolio and pricing power?

Earnings

9 days ago

Read more businesswire

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report...

What is the status of the company's pipeline and any upcoming product milestones that could drive future revenue? Did the company address any regulatory or reimbursement developments that could affect its business model? Are there any risks or uncertainties highlighted in the earnings call that could impact the company's future performance?

Earnings

15 days ago

Read more businesswire

Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focu...

What is the projected impact of this strategy on Allurion's share volume and price volatility in the next 12 months? Are there any licensing or IP considerations tied to the low‑dose GLP‑1 combination that could affect future earnings? What are the potential risks if patient adherence to behavior‑change protocols does not meet expectations?

Strategy

17 days ago

Read more businesswire

Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the American Society for Met...

Clinical trials

2 months ago

Read more businesswire